HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.

AbstractBACKGROUND:
TSC2-deficient cells can proliferate in the lungs, kidneys, and other organs causing devastating progressive multisystem disorders such as lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Preclinical models utilizing LAM patient-derived cells have been difficult to establish. We developed a novel animal model system to study the molecular mechanisms of TSC/LAM pathogenesis and tumorigenesis and provide a platform for drug testing.
METHODS AND FINDINGS:
TSC2-deficient human cells, derived from the angiomyolipoma of a LAM patient, were engineered to co-express both sodium-iodide symporter (NIS) and green fluorescent protein (GFP). Cells were inoculated intraparenchymally, intravenously, or intratracheally into athymic NCr nu/nu mice and cells were tracked and quantified using single photon emission computed tomography (SPECT) and computed tomography (CT). Surprisingly, TSC2-deficient cells administered intratracheally resulted in rapid dissemination to lymph node basins throughout the body, and histopathological changes in the lung consistent with LAM. Estrogen was found to be permissive for tumor growth and dissemination. Rapamycin inhibited tumor growth, but tumors regrew after the drug treatment was withdrawn.
CONCLUSIONS:
We generated homogeneous NIS/GFP co-expressing TSC2-deficient, patient-derived cells that can proliferate and migrate in vivo after intratracheal instillation. Although the animal model we describe has some limitations, we demonstrate that systemic tumors formed from TSC2-deficient cells can be monitored and quantified noninvasively over time using SPECT/CT, thus providing a much needed model system for in vivo drug testing and mechanistic studies of TSC2-deficient cells and their related clinical syndromes.
AuthorsFangbing Liu, Elaine P Lunsford, Jingli Tong, Yoshitomo Ashitate, Summer L Gibbs, Jane Yu, Hak Soo Choi, Elizabeth P Henske, John V Frangioni
JournalPloS one (PLoS One) Vol. 7 Issue 6 Pg. e38589 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22719903 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents
  • TSC2 protein, human
  • Tsc2 protein, mouse
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Suppressor Proteins
  • Green Fluorescent Proteins
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Blotting, Western
  • Cell Transformation, Neoplastic
  • Disease Models, Animal
  • Green Fluorescent Proteins (genetics)
  • Humans
  • Lymphangioleiomyomatosis (drug therapy, pathology)
  • Mice
  • Mice, Nude
  • Microscopy, Fluorescence
  • Monitoring, Physiologic (methods)
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed
  • Tuberous Sclerosis (drug therapy, pathology)
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Cells, Cultured
  • Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: